Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non–Small Cell Lung Cancer

Developing proteomic biomarkers is valuable for evaluating therapeutic effects of drugs and generating better treatment strategies. However, conventional protein analysis is often challenging due to inadequate sample size of clinical specimens, lack of assay reproducibility, accuracy, and sensitivity. A novel capillary isoelectricfocusing (IEF) immunoassay system (NanoPro) was used to study the dynamic phosphorylation status of signaling molecules in non–small cell lung cancer (NSCLC) cells treated with EGFR tyrosine kinase and MEK inhibitors. NanoPro showed the same dynamic ERK phosphorylation as Western blotting with good assay reproducibility using 1,000 times less protein. The IEF separation in NanoPro system enables multiple protein phosphorylation isoforms to be resolved and detected simultaneously. With NanoPro, we identified a specific on-target mitogen-activated protein/extracellular signal–regulated kinase (MEK) response pattern to MEK inhibitor PD325901, which was not detectable by Western blot analysis. We also revealed a MEK2 signal that may be associated with NSCLC cell sensitivity to the EGF receptor inhibitor erlotinib, and distinguished erlotinib-sensitive cells from intrinsic as well as acquired resistant cells to erlotinib. Moreover, NanoPro could differentiate human ERK1 isoforms from the mouse isoforms based on their isoelectric point differences and showed that erlotinib effectively inhibited ERK phosphorylation in targeted human xenograft cancer cells but not in surrounding mouse stromal cells. With 8 μg of tumor aspirates, we precisely quantified the response of 18 signaling molecules to erlotinib and MEK1 inhibitor treatments in an NSCLC patient. NanoPro's higher sensitivity, better resolution of protein phosphorylation status, and reduced tissue requirement warrant NanoPro's investigation for future drug development and evaluation of drug effects of targeted therapies. Mol Cancer Ther; 12(11); 2601–13. ©2013 AACR.

[1]  L. Wakefield,et al.  Biological Responses to TGF-β in the Mammary Epithelium Show a Complex Dependency on Smad3 Gene Dosage with Important Implications for Tumor Progression , 2012, Molecular Cancer Research.

[2]  Andrew L. Kung,et al.  Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia , 2012, Nature Medicine.

[3]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[4]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[5]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Bardelli,et al.  Targeted therapies: how personal should we go? , 2012, Nature Reviews Clinical Oncology.

[7]  Charles P. Lin,et al.  Defining the role of TORC1/2 in multiple myeloma. , 2011, Blood.

[8]  P. Meltzer,et al.  Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer , 2011, Clinical Cancer Research.

[9]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[10]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[11]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[12]  Juri G. Gelovani,et al.  Methodological and practical challenges for personalized cancer therapies , 2011, Nature Reviews Clinical Oncology.

[13]  Richard Z. Liu,et al.  Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. , 2011, Journal of proteome research.

[14]  D. Felsher,et al.  Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. , 2010, Leukemia research.

[15]  Razelle Kurzrock,et al.  Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse , 2010, Clinical Cancer Research.

[16]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[17]  Larry Rubinstein,et al.  Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yasodha Natkunam,et al.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.

[19]  I Judson,et al.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? , 2009, British Journal of Cancer.

[20]  J. Warmus,et al.  The Discovery of the Benzhydroxamate MEK Inhibitors CI‐1040 and PD 0325901. , 2009 .

[21]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[22]  Koichi Yokota,et al.  Crystal structure of human mono-phosphorylated ERK1 at Tyr204. , 2008, Biochemical and biophysical research communications.

[23]  J. Möcks,et al.  A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy , 2008, Clinical Cancer Research.

[24]  W. Pao,et al.  Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Tortora,et al.  The use of xenograft models for the selection of cancer treatments with the EGFR as an example. , 2008, Critical reviews in oncology/hematology.

[26]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[27]  Xiahui Bi,et al.  Isoelectric focusing technology quantifies protein signaling in 25 cells , 2006, Proceedings of the National Academy of Sciences.

[28]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[29]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[30]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[32]  T. Seidal,et al.  Interpretation and Quantification of Immunostains , 2001, The American journal of surgical pathology.

[33]  G. Johnson,et al.  MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. , 1994, Molecular biology of the cell.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[35]  E. Goldsmith,et al.  Structural analysis of the MAP kinase ERK2 and studies of MAP kinase regulatory pathways. , 1996, Advances in pharmacology.